Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064631 | 1.00 | DRD2 (0.48) | DRD2DRD3 | |
| SCHEMBL5428492 | 0.88 | DRD2 (0.47) | DRD2DRD3 | |
| SCHEMBL5428488 | 0.88 | DRD2 (0.47) | DRD2DRD3 | |
| Formic Acid SCHEMBL4071546 | 0.86 | DRD2 (0.52) | DRD2DRD3 | |
| Formic Acid SCHEMBL4071543 | 0.86 | DRD2 (0.52) | DRD2DRD3 | |
| SCHEMBL4070649 | 0.83 | DRD2 (0.49) | DRD2DRD3 | |
| SCHEMBL4070656 | 0.83 | DRD2 (0.49) | DRD2DRD3 | |
| Formic Acid SCHEMBL4073803 | 0.83 | DRD2 (0.55) | DRD2DRD3 | |
| Formic Acid SCHEMBL4073816 | 0.83 | DRD2 (0.55) | DRD2DRD3 | |
| SCHEMBL4070309 | 0.82 | DRD2 (0.53) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725240-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | claimed |
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| EP-1725240-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | claimed |
| WO-2005094834-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | claimed |
| EP-1725240-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1725240-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005094834-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | CHRM3, CHRNG, CHRM2 | DRD2 969/4885DRD3 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.